On a global basis, stem cell clinics have proliferated in recent years. This article explores stem cell centers within the U.S. and worldwide. Read on to learn about this emerging area of medicine. [Read more…]
Overcoming major challenges in cardiac drug discovery using human induced pluripotent stem cell technology
Source/Author: Ncardia, Galileiweg 8 | 2333 BD Leiden | The Netherlands
Highlights
- The biggest opportunity for success in cardiac drug discovery and development is to make these processes more efficient and affordable, since they carry relatively higher risk of clinical trial failure compared to other disciplines.
- Human iPSC technology is increasingly utilized to develop disease models that reliably mimic the diversity of patient pathogenicity and disease severity in vitro.
- Phenotypic screening based on iPSC-derived disease models is making cardiac drug discovery more time and cost effective by enabling target-agnostic studies and increasing the translational power of early drug discovery outcomes.
REPROCELL Introduces StemEdit Platform
AI-Designed Genome Editors & Hypoimmune iPSC Lines
*Sponsored Content: The article is sponsored by REPROCELL.
REPROCELL has launched StemEdit, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system. The platform integrates high-fidelity genome engineering with predictive off-target modelling, designed to support research, translational development and future clinical applications. [Read more…]
Takara Bio Establishes Foothold in the Pluripotent Stem Cell Market
*Sponsored Content: The article is sponsored by Takara Bio.
A few years back, Takara Bio 
announced that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation of drug and medical products, had granted the company a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions. The cells were to be produced at Takara Bio’s manufacturing laboratory located in Göteborg, Sweden, within Takara Bio Europe’s facility.
This announcement made Takara Bio the first company worldwide to offer this service for human ESCs.
Takara Bio’s Role with Human Pluripotent Stem Cells
The significance of this event is that Takara Bio is capable of providing a predictable and reliable source of hES cells for future cellular therapeutic development by sourcing starting material from FDA-compliant facilities, according to FDA guidelines and leveraging its proprietary, feeder-free hES cell establishment method, which is animal- and human-component free. [Read more…]
Cutting-Edge Hair Restoration Techniques in 2027
*This article contains sponsored content.
Hair loss affects millions worldwide, which has driven rapid innovation in hair restoration science. In 2026, the latest advancements combine regenerative medicine, stem cell therapy, and minimally invasive procedures to deliver natural, lasting results. These cutting-edge hair restoration techniques are redefining what’s possible for both men and women seeking to restore their hair growth and confidence.
In this article, we highlight the most advanced and effective hair restoration methods available today, as we enter 2027.
[Read more…]